Back

Safety profile of acoramidis in cardiac amyloidosis: insights from post-marketing pharmacovigilance data

11 May 2026 (17:27 - 17:36)
Organised by: Logo
Congress Presentation Part of: Transthyretin amyloidosis: long-term outcomes and emerging therapies Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Joyce Gu

Erie (United States of America)

6 More presentations in this session

Presentation thumbnail
Vutrisiran-mediated knockdown of transthyretin in patients with transthyretin amyloidosis
Doctor V. Algalarrondo (Paris, FR)
Abstract Slides Video
Presentation thumbnail
CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results
Doctor Y. Razvi (London, GB)
Abstract Slides Video
Presentation thumbnail
Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study
Doctor T. Damy (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
A trial emulation study comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy using calibration and indirect treatment comparison methods: the ReplicATTR Study
Doctor P. Zwetsloot (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis
Doctor A. Abovich (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Transthyretin amyloidosis: long-term outcomes and emerging therapies
Video

The Event

Event poster

Heart Failure 2026

11 May 2026 17:27 CET
You may be interested in
thumbnail
Congress Session
Transthyretin amyloidosis: long-term outcomes and emerging therapies
thumbnail
Congress Session
Advances in amyloidosis
thumbnail
Congress Session
Therapeutic advances in amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources